Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Therapy01:28

Drug Therapy

47
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
47
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

289
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
289
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

143
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
143
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

221
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
221
Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

202
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
202
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

252
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
252

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world use of xanomeline/trospium chloride in a large academic healthcare system in the first year following FDA approval.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2026
Same author

Associations between negative symptoms and thermal pain perception in bipolar I disorder.

International journal of bipolar disorders·2025
Same author

Identifying psychosis episodes in psychiatric admission notes via rule-based methods, machine learning, and pre-trained language models.

Translational psychiatry·2025
Same author

Real-time fMRI neurofeedback modulates auditory cortex activity and connectivity in schizophrenia patients with auditory hallucinations: A controlled study.

Psychiatry research. Neuroimaging·2025
Same author

Machine learning in psychiatric health records: A gold standard approach to trauma annotation.

Translational psychiatry·2025
Same author

Method-specific suicide mortality rates among older adults in 47 countries and territories, 1996-2021, with projections to 2050: a global time series and modelling study.

The lancet. Healthy longevity·2025

Related Experiment Video

Updated: Jul 12, 2025

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

6.7K

Medication Adherence in a Transdiagnostic First-Episode Psychosis Sample.

Stephanie M London1,2,3, Philip B Cawkwell1,2, Ann K Shinn1,2

  • 1Psychotic Disorders Division, McLean Hospital, Belmont, Massachusetts.

The Journal of Clinical Psychiatry
|November 2, 2023
PubMed
Summary

Medication adherence in first-episode psychosis (FEP) is crucial. Non-White race, poor insight, and substance use predict non-adherence, highlighting areas for clinical intervention.

More Related Videos

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis
05:52

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis

Published on: November 21, 2013

15.0K
The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
05:48

The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients

Published on: June 12, 2020

5.8K

Related Experiment Videos

Last Updated: Jul 12, 2025

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

6.7K
Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis
05:52

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis

Published on: November 21, 2013

15.0K
The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
05:48

The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients

Published on: June 12, 2020

5.8K

Area of Science:

  • Psychiatry
  • Clinical Psychology
  • Pharmacology

Background:

  • Medication adherence significantly impacts treatment outcomes in first-episode psychosis (FEP).
  • Understanding predictors of non-adherence is vital for improving patient trajectories.
  • Real-world data from FEP clinics are essential for informing clinical practice.

Purpose of the Study:

  • To investigate the time to medication non-adherence in a real-world FEP clinic.
  • To identify demographic and clinical factors associated with medication non-adherence in FEP patients.

Main Methods:

  • Survival analysis was employed using data from 219 patients in an academic psychiatric hospital's FEP clinic (May 2012-Oct 2017).
  • The study focused on 122 patients adherent for the initial 6 months, analyzing data up to 66 months.
  • Cox proportional hazards models were used to assess predictors of non-adherence.

Main Results:

  • Of 122 patients, 30% experienced non-adherence events.
  • The risk of non-adherence was 35% at 24 months and 49% at 36 months, plateauing thereafter.
  • Significant predictors included non-White race (aHR=3.69), lack of insight (aHR=3.24), and substance use (aHR=2.58).

Conclusions:

  • Interventions targeting therapeutic alliance, insight, and substance use are critical for enhancing medication adherence in FEP.
  • Addressing these factors may improve long-term outcomes for individuals with first-episode psychosis.
  • Clinical strategies should be tailored to mitigate identified risks for non-adherence.